Calyx Therapeutics Announces Issuance of U.S. Patent on Orally Active Peptides for Treatment of Diabetes.Health/Medical Writers HAYWARD, Calif.--(BW HealthWire)--Oct. 11, 2000 Calyx calyx (kā`lĭks): see sepal. Therapeutics, a San Francisco Bay Area “Bay Area” redirects here. For other uses, see Bay Area (disambiguation). The San Francisco Bay Area, colloquially known as the Bay Area or The Bay drug development company, today announced the issuance of a U.S. patent on a series of small peptides potentially useful for the treatment of diabetes. U.S. Patent 6,127,338 claims sequences and pharmaceutical compositions of three orally active peptides that lower blood glucose levels blood glucose level, n level of glu-cose in the bloodstream, normally about 70 to 115 mg/dL after fasting overnight. Higher levels may indicate diseases such as diabetes mellitus. in animal models of diabetes. The patent expands Calyx's intellectual property in the area of novel, orally active antidiabetic compounds. The largest of the three peptides, now designated CLX-0100, is an 18-amino-acid peptide isolated by Calyx from the extract of a tropical plant known for its glucose-lowering activity. The other two peptides claimed in the patent are truncated forms of CLX-0100, comprising the first 11 and seven amino acids of the natural isolate. Founded in 1997 and located in Hayward, California Hayward is a city located in the East Bay in Alameda County. The sixth largest city in the San Francisco Bay Area, it is one of the larger suburbs of Oakland. As of the 2000 census, the city population was 140,030. The estimated population in 2007 is 155,312. , Calyx utilizes natural plant and animal extracts with demonstrated clinical activity in humans as the starting point Noun 1. starting point - earliest limiting point terminus a quo commencement, get-go, offset, outset, showtime, starting time, beginning, start, kickoff, first - the time at which something is supposed to begin; "they got an early start"; "she knew from the for its research efforts. The company isolates the active ingredient, determines its chemical structure and develops rational small molecule analogs. Calyx is pursuing small molecule drug development efforts in the areas of diabetes, inflammation and allergy. In addition to four lead antidiabetic compounds, the company is currently developing two anti-inflammatory compounds for treatment of rheumatoid arthritis rheumatoid arthritis Chronic, progressive autoimmune disease causing connective-tissue inflammation, mostly in synovial joints. It can occur at any age, is more common in women, and has an unpredictable course. . |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion